Karyopharm Therapeutics Inc. (KPTI) intrinsic value & 10-year financials
Karyopharm Therapeutics Inc. (KPTI) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 10 fiscal years revenue grew 114.2% a year to $146.1M, with an average return on invested capital of 160.5%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $0.39
- Market cap
- $4.3K
- Revenue (FY2025)
- $146.1M
- Revenue growth (10-yr CAGR)
- 114.2%
- ROIC (10-yr avg)
- 160.5%
- Free cash flow (FY2025)
- —
KPTI 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $146.1M | -$196.0M | -$17.93 | — | -62.1% | 30.8% |
| FY2024 | $145.2M | -$76.4M | -$0.93 | -$127.6M | -82.2% | 55.9% |
| FY2023 | $146.0M | -$143.1M | -$1.25 | — | -88.7% | 78.2% |
| FY2022 | $157.1M | -$165.3M | -$2.02 | -$149.7M | -90.5% | 119.7% |
| FY2021 | $209.8M | -$124.1M | -$1.65 | -$107.3M | -46.8% | 169.5% |
| FY2020 | $108.1M | -$196.3M | -$2.72 | -$160.4M | -159.0% | 382.0% |
| FY2019 | $40.9M | -$199.6M | — | -$191.0M | -462.9% | 287.3% |
| FY2018 | $30.3M | -$178.4M | — | -$161.5M | -593.0% | — |
| FY2017 | $1.6M | -$129.0M | — | -$73.8M | -8133.2% | — |
| FY2016 | $154.0K | -$109.6M | — | -$84.5M | -71903.9% | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Karyopharm Therapeutics Inc. is a consistent compounder, expanding top-line revenue at 114.2% annually over the past decade.
Karyopharm Therapeutics Inc. has earned high returns on invested capital, averaging 41.8% ROIC over the available history. High ROIC is consistent with a durable franchise, but it is not by itself proof of an economic moat.
Karyopharm Therapeutics Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Karyopharm Therapeutics Inc. is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-595.56 per share.